FDA Denies Majority Of Requests To Reclassify Low-Risk De Novo Devices
This article was originally published in The Gray Sheet
Executive Summary
Close to 63% of requests to FDA seeking Class I or Class II status for de novo devices without a predicate have been denied to date, FDA staffers say.
You may also be interested in...
Future 510(k) NSE Letters May Indicate If Alternative Classification Feasible
FDA may indicate in future "not substantially equivalent" 510(k) letters whether or not the sponsor's device is a likely candidate for placement in Class I or Class II using the new alternative low-risk de novo device classification process established by Sec. 207 of the FDA Modernization Act.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.